YOLFTbeta
Aelis Farma SA

Aelis Farma SA

AELIS · PA · Healthcare / Biotechnology

0.92EUR+0.05 (+5.14%)

Price History

Full chart

Market Stats

Previous Close0.875
Open0.88
Day Range0.88 – 0.92
52-Week Range0.87 – 2.30
Volume12.54K
Market Cap11.93M
P/E (TTM)0.00
Forward P/E0.00
EPS-0.33
Dividend Yield0.00%
Beta0.62
50-Day Avg0.9962
200-Day Avg1.18

About

Aelis Farma SA, a clinical-stage biopharmaceutical company, focuses on discovering and developing drug candidates for the treatment of central nervous system disorders in France. The company owns a pipeline of pharmacological inhibitors, including AEF0117, a drug candidate, which is in Phase 2b clinical trials for the treatment of the harmful effects of excessive cannabis use; AEF0217, a drug candidate, which is in phase 1/2 clinical trials to treat cognitive deficits observed in down syndrome; and CB1-SSi, a new molecular entities to treat other CB1-dependent diseases, including several orphan diseases. Aelis Farma SA was incorporated in 2013 and is headquartered in Bordeaux, France.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEODr. Pier Vincenzo Piazza M.D., Ph.D.
  • Employees14
  • Headquarters1 rue Lafaurie de Monbadon, Bordeaux, France, 33000, France
  • Websitehttps://www.aelisfarma.com

Leadership

  • Dr. Pier Vincenzo Piazza M.D., Ph.D.CEO & Director · b. 1961
  • Stephanie MonlezunChief Operating Officer

Financials

Income Statement

Currency: EUR2017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue85.47K39.96K8.85K1.14M9.07M3.81M9.05M2.68M2.08M
Growth (%)--53.25%-77.85%+12746.01%+698.15%-58.03%+137.70%-70.42%-22.18%
Cost of Revenue2.26M2.90M3.13M30.00K---3.30M5.56M-
Gross Profit-2.17M-2.86M-3.13M1.11M9.07M3.81M9.05M2.68M-279.00K
Gross Margin-2541.09%-7149.97%-35314.31%97.36%100.00%100.00%100.00%100.00%-13.39%
Operating Expense-185.63K-225.98K-135.67K5.15M6.52M12.33M15.52M10.41M8.00M
Operating Income-1.99M-2.63M-2.99M-4.05M2.55M-8.53M-6.46M-7.74M-8.28M
Operating Margin-2323.90%-6584.41%-33781.49%-355.85%28.12%-223.81%-71.36%-288.83%-397.36%
EBITDA-1.99M-3.48M-4.51M-3.57M844.00K-16.23M-6.35M-7.18M-8.00M
EBITDA Margin-2322.44%-8698.02%-50972.00%-313.63%9.30%-426.02%-70.10%-268.11%-383.97%
Net Income-1.00M-2.73M-3.17M-2.09M574.00K-14.29M-5.08M-7.46M-6.43M
Net Income Margin-1173.24%-6834.68%-35826.46%-183.47%6.33%-375.11%-56.09%-278.42%-308.73%
R&D-3.39M4.08M3.39M6.87M13.79M16.21M9.94M5.77M
R&D as % of Total Revenue-8488.91%46085.19%297.98%75.70%362.09%179.06%371.25%276.78%
Interest Expense-62.00K104.00K138.00K140.00K112.00K157.00K206.00K287.00K
Interest Expense % of Total Revenue-155.16%1175.01%12.14%1.54%2.94%1.73%7.69%13.77%

Balance Sheet

Currency: EUR2017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets6.29M6.30M7.22M7.00M28.31M39.22M26.28M19.71M12.05M
Total Liabilities4.60M3.92M6.02M7.71M27.41M19.43M13.08M9.59M7.61M
Total Equity1.68M2.38M1.20M-710.00K899.00K19.79M13.20M10.12M4.44M
Cash4.57M5.12M5.77M4.54M24.71M34.40M20.23M14.05M8.21M
Total Debt2.23M3.08M4.65M6.11M6.41M3.82M4.04M6.25M6.60M
Net Debt-2.33M-2.04M-1.12M1.58M-18.30M-30.57M-16.19M-7.80M-1.61M

Cash Flow

Currency: EUR2017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow--3.55M-2.89M-2.48M18.97M-13.05M-12.59M-11.83M-5.38M
Investing Cash Flow--15.00K-36.00K-34.00K-212.00K-86.00K-88.00K-190.00K-841.00K
Financing Cash Flow-4.12M3.57M1.28M180.00K22.10M-1.34M5.81M538.00K
Capital Expenditure018.00K36.00K35.00K213.00K137.00K88.00K190.00K4.00K
Free Cash Flow--3.57M-2.92M-2.51M18.76M-13.19M-12.67M-11.72M-5.39M
FCF to OCF-100.51%101.25%101.41%98.88%101.05%100.70%99.04%100.07%

Earnings

Report DateFeb 3, 2022Apr 26, 2022Sep 26, 2022Apr 3, 2023Apr 29, 2025Sep 22, 2025Sep 15, 2026Mar 30, 2027
EPS Estimate0.000.000.000.000.000.00--
EPS Actual-0.11-0.26-0.93-0.28-0.28-0.32--
Surprise--------
TimingAfter-hours-After-hoursAfter-hours--After-hoursAfter-hours

Key Statistics & Ratios

Market Cap11.93M
Enterprise Value9.90M
Trailing P/E0.00
Forward P/E0.00
Price / Sales5.44
Price / Book2.70
EPS-0.33
Book Value0.326
Revenue (TTM)2.19M
Gross Profit (TTM)3.58M
EBITDA-4.40M
Profit Margin-216.29%
Operating Margin-601.56%
Return on Equity-112.53%
Return on Assets-23.40%
Shares Outstanding13.63M
Shares Float4.07M
Beta0.62
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%